Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFFRON study of savolitinib + osimertinib versus platinum-pemetrexed chemotherapy in EGFR-mutated, MET-positive advanced NSCLC after osimertinib progression
jRCT2031220420Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Randomised, open-label trial of savolitinib, osimertinib, cisplatin, carboplatin and pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Nov 2022; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031220420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220420.